^
    Back
    Association details:
    Biomarker:CALR mutation
    Cancer:Myelodysplastic Syndrome
    Drug:Reblozyl (luspatercept-aamt) (TGFβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Myelodysplastic syndromes: Frequent Mutations...CALR...Treatment: luspatercept-aamt...